Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry
Puntos clave
The research aims to evaluate the impact of inosine pranobex on mortality rates in COVID-19 patients.
Retrospective study design
Utilized complete health data from the Czech national registry
Focused on COVID-19 patient outcomes
Inosine pranobex administration was associated with a reduction in mortality by over 22% in COVID-19 patients.
The findings support further investigation into the drug's therapeutic benefits.
Resumen
IP administration in COVID-19 patients was associated with reduced mortality, supporting the need for further investigation of its therapeutic potential.
Inosine pranobex was associated with a reduction in mortality in COVID-19 by over 22%, as reported in a retrospective study utilizing complete health data from the Czech national registry | Synapse